- Home
- IGMS vs NXC Comparison
IGMS vs NXC Comparison
Compare IGMS & NXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- NXC
- Stock Information
- Founded
- IGMS 1993
- NXC 1992
- Country
- IGMS United States
- NXC United States
- Employees
- IGMS N/A
- NXC N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- NXC Investment Managers
- Sector
- IGMS Health Care
- NXC Finance
- Exchange
- IGMS Nasdaq
- NXC Nasdaq
- Market Cap
- IGMS 82.1M
- NXC 82.6M
- IPO Year
- IGMS 2019
- NXC N/A
- Fundamental
- Price
- IGMS $1.38
- NXC $13.10
- Analyst Decision
- IGMS Hold
- NXC
- Analyst Count
- IGMS 8
- NXC 0
- Target Price
- IGMS $6.14
- NXC N/A
- AVG Volume (30 Days)
- IGMS 368.0K
- NXC 17.5K
- Earning Date
- IGMS 03-06-2025
- NXC 01-01-0001
- Dividend Yield
- IGMS N/A
- NXC 3.97%
- EPS Growth
- IGMS N/A
- NXC N/A
- EPS
- IGMS N/A
- NXC 0.19
- Revenue
- IGMS $2,918,000.00
- NXC N/A
- Revenue This Year
- IGMS $26.85
- NXC N/A
- Revenue Next Year
- IGMS $125.17
- NXC N/A
- P/E Ratio
- IGMS N/A
- NXC $70.47
- Revenue Growth
- IGMS 57.64
- NXC N/A
- 52 Week Low
- IGMS $1.26
- NXC $11.86
- 52 Week High
- IGMS $22.50
- NXC $13.70
- Technical
- Relative Strength Index (RSI)
- IGMS 26.21
- NXC 48.44
- Support Level
- IGMS $1.26
- NXC $13.00
- Resistance Level
- IGMS $1.54
- NXC $13.19
- Average True Range (ATR)
- IGMS 0.13
- NXC 0.09
- MACD
- IGMS 0.22
- NXC -0.00
- Stochastic Oscillator
- IGMS 29.27
- NXC 25.64
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing primarily in municipal obligations.